Evidence map›Paper›PMID 30041641›Full record

ArticleBMC complementary and alternative medicine2018

Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities.

Anchalee Prasansuklab, Atsadang Theerasri, Matthew Payne, Alison T Ung, Tewin Tencomnao

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Pharmaceutical biology · 2021
    Article
  4. Review
  5. Effect ofAdvances in pharmacological and pharmaceutical sciences · 2021
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Anchalee PrasansuklabProgram in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Atsadang TheerasriProgram in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Matthew PayneSchool of Mathematical and Physical Sciences, Faculty of Science, The University of Technology Sydney, Sydney, NSW, 2007, Australia.
Alison T UngSchool of Mathematical and Physical Sciences, Faculty of Science, The University of Technology Sydney, Sydney, NSW, 2007, Australia. Alison.Ung@uts.edu.au.
Tewin TencomnaoAge-Related Inflammation and Degeneration Research Unit, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. tewin.t@chula.ac.th.
Chulalongkorn University · THUniversity of Technology Sydney · AU

Funding

Chulalongkorn University 90th anniversary of Chulalongkorn University fundChulalongkorn University Overseas Research Experience Scholarship for Graduate Student and a Grant for Joint Funding, Ratchadaphiseksomphot Endowment Fund
6 · The paper itself

Abstract

backgroundStreblus asper is a well-known plant native to Southeast Asia. Different parts of the plant have been traditionally used for various medicinal purposes. However, there is very little scientific evidence reporting its therapeutic benefits for potential treatment of Alzheimer's disease (AD). The study aimed to evaluate antibacterial, antioxidant, acetylcholinesterase (AChE) inhibition, and neuroprotective properties of S. asper leaf extracts with the primary objective of enhancing therapeutic applications and facilitating activity-guided isolation of the active chemical constituents.

methodsThe leaves of S. asper were extracted in ethanol and subsequently fractionated into neutral, acid and base fractions. The phytochemical constituents of each fraction were analyzed using GC-MS. The antibacterial activity was evaluated using a broth microdilution method. The antioxidant activity was determined using DPPH and ABTS radical scavenging assays. The neuroprotective activity against glutamate-induced toxicity was tested on hippocampal neuronal HT22 cell line by evaluating the cell viability using MTT assay. The AChE inhibitory activity was screened by thin-layer chromatography (TLC) bioautographic method.

resultsThe partition of the S. asper ethanolic leaf extract yielded the highest mass of phytochemical constitutions in the neutral fraction and the lowest in the basic fraction. Amongst the three fractions, the acidic fraction showed the strongest antibacterial activity against gram-positive bacteria. The antioxidant activities of three fractions were found in the order of acidic > basic > neutral, whereas the decreasing order of neuroprotective activity was neutral > basic > acidic. TLC bioautography revealed one component in the neutral fraction exhibited anti-AChE activity. While in the acid fraction, two components showed inhibitory activity against AChE. GC-MS analysis of three fractions showed the presence of major phytochemical constituents including terpenoids, steroids, phenolics, fatty acids, and lipidic plant hormone.

conclusionsOur findings have demonstrated the therapeutic potential of three fractions extracted from S. asper leaves as a promising natural source for neuroprotective agents with additional actions of antibacterials and antioxidants, along with AChE inhibitors that will benefit in the development of new natural compounds in therapies against AD.

Indexed as

AnimalsAnti-Bacterial AgentsAntioxidantsBacteriaBiphenyl CompoundsCell LineCell SurvivalCholinesterase InhibitorsGas Chromatography-Mass SpectrometryHippocampusMiceMoraceaeNeuroprotective AgentsPicratesPlant ExtractsPlant Leaves1,1-diphenyl-2-picrylhydrazylAnti-Bacterial AgentsAntioxidantsBiphenyl CompoundsCholinesterase InhibitorsNeuroprotective AgentsPicratesPlant ExtractsAcid-base extractionAlzheimer’s diseaseGlutamate toxicityHT22 cellsNeurodegenerative diseasesNeuroprotectionStreblus asper

Identifiers

PMID30041641
PMCPMC6057052
OpenAlexW2883113960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.